Patricia Inácio, PhD, science writer —

Treatment with Ascendis Pharma’s TransCon PTH (palopegteriparatide) for up to two years leads to sustained improvements in the kidney function of adults with chronic hypoparathyroidism. That’s according to an analysis of data from PaTHway (NCT04701203), a Phase 3 clinical trial of TransCon PTH. A decision from the…

People with higher body fat — as measured by body mass index, or BMI — have a lower risk of developing hypoparathyroidism following total thyroidectomy, a surgery that completely removes the thyroid glands, a new study reports. Besides body fat, levels of parathyroid hormone (PTH) before surgery and a…

A natural history study of hypoparathyroidism taking place at Columbia University Irving Medical Center in New York has started to enroll adult patients. The study, called SHINE (NCT05793853), is recruiting an estimated 94 people, ages 18 and older, with any hypoparathyroidism subtype and undergoing any type of treatment…

Amolyt Pharma has raised €130 million (roughly $138 million) to support the clinical development of eneboparatide, previously AZP-3601, the company’s experimental therapy for hypoparathyroidism. The funding will be used in Phase 3 testing of the treatment and will also help develop AZP-3813 for acromegaly, which occurs when…

Central lymph node dissection, or the removal of lymph nodes in the neck, increases the risk of both temporary and permanent post-surgical hypoparathyroidism in people with thyroid cancer who undergo surgery to remove the thyroid gland, a 10-year French study reports Also, lateral lymph node dissection along with total…

The U.S. Food and Drug Administration (FDA) has greenlit an expanded access program (EAP) for Ascendis Pharma to allow certain adults with hypoparathyroidism to receive TransCon PTH, an investigational parathyroid hormone (PTH) replacement therapy. An EAP allows patients with life-threatening or serious diseases access to investigational therapies…

Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the company has announced. The request, submitted as a marketing authorization application (MAA) to the European Medicines Agency (EMA), follows a similar application submitted in September to the U.S.

Less experienced surgeons and removing lymph nodes in the neck during thyroid surgery are the main risk factors of accidentally damaging the neighboring parathyroid glands, which can cause hypoparathyroidism, a large study in China showed. A surgeon’s inexperience and a more advanced thyroid tumor also increased the risk of…

Daily treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely and effectively normalizes calcium levels in people with the disease, according to data from the second group of patients in a proof-of-concept Phase 2a clinical trial. Most participants stopped calcium and vitamin D supplements, which is the…

The HypoPARAthyroidism Association has launched the first-of-its-kind Patient-Powered Data Platform, a repository to help understand the disease journey and develop better treatments for people with hypoparathyroidism. Interested participants — patients, caregivers, or those who have lost a loved one to the rare disease — can enter patient…